Mineralys Therapeutics, Inc. (MLYS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

35/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

35

Weakening

Sentiment

40

Bearish

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Jon Congleton
Listed since: Feb 10, 2023
Employees: 76

Market position

Day range

Current $25.65

$25.63$26.3999

52-week range

Current $25.65

$14.53$47.65

Open: $25.97
Previous close: $25.75
Volume: 699.84K; 0.54× average
Average volume: 1.3M; Average daily volume
Market cap: 2.26B USD
Beta: 0.68; Market reference 1
50-day average: $26.6451; -3.73% below average
200-day average: $30.3921; -15.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.28B USD
P/E (TTM): -6.05×
P/B (TTM): 3.94×
P/S (TTM): 0×
EV / EBITDA: -14.76×
Earnings yield: -6.30%
Free cash flow yield: -5.80%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -23.91%
Return on assets: -23.37%
Return on invested capital: -26.38%

Financial health

Debt / equity: 0.18×
Current ratio: 43.76×

Financial statements

Income trends

Operating income

−170.6M USD+11.33%

Net income

−154.65M USD+13.02%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	132.01M USD	168.58M USD	70.36M USD	26.25M USD	16.31M USD
Selling, general, and administrative	38.6M USD	23.82M USD	14.3M USD	5.23M USD	2.42M USD
Operating expenses	170.6M USD	192.4M USD	84.66M USD	31.48M USD	18.73M USD
Interest income	15.95M USD	14.59M USD	12.76M USD	1.68M USD	—
Interest expense	—	—	—	1.68M USD	27K USD
Depreciation and amortization	59K USD	43K USD	—	—	—
Operating income	−170.6M USD	−192.4M USD	−84.66M USD	−31.48M USD	−18.73M USD
Net income	−154.65M USD	−177.81M USD	−71.9M USD	−29.8M USD	−19.41M USD